The Future of MPS I Treatment: Gene Therapies Poised to Revolutionize Care

Health Mar 18, 2025 5 Add to Reading List

Mucopolysaccharidosis I (MPS I) is a rare genetic disorder caused by the deficiency of the α-L-iduronidase enzyme. This deficiency results in the accumulation of glycosaminoglycans (GAGs), which progressively damage multiple organs and systems. Patients with MPS I may experience skeletal deformities, respiratory complications, vision and hearing impairments, and neurological decline. The condition presents in three forms: Hurler syndrome (severe), Hurler-Scheie syndrome (intermediate), and Scheie syndrome (mild).

The growing awareness of rare diseases, combined with advancements in gene therapy and evolving treatment approaches, is driving expansion in the Mucopolysaccharidosis I Market Size. This article delves into the current Mucopolysaccharidosis I Treatment Market landscape and explores the latest developments in the Mucopolysaccharidosis I Drugs Market.

Mucopolysaccharidosis I Market Size and Epidemiology

The global Mucopolysaccharidosis I Market Size is influenced by several factors, including disease prevalence, advancements in therapeutics, and regulatory approvals. Although rare, MPS I has an estimated incidence rate of 1 in 100,000 live births worldwide. The market is expected to expand as a result of improved diagnostic techniques, increased adoption of newborn screening programs, and greater healthcare provider awareness.

Key factors driving market growth include:

Rising investments in rare disease research
Ongoing innovations in enzyme replacement therapies (ERT) and gene therapies
Government initiatives promoting orphan drug development
Strategic alliances between biotech and pharmaceutical firms

Mucopolysaccharidosis I Treatment Market: Current Landscape

The Mucopolysaccharidosis I Treatment Market primarily relies on enzyme replacement therapy (ERT), hematopoietic stem cell transplantation (HSCT), and supportive care.

1. Enzyme Replacement Therapy (ERT)
ERT remains the standard treatment for MPS I. Laronidase (Aldurazyme), developed by BioMarin and Sanofi, is the only FDA-approved ERT for MPS I. It supplements the deficient α-L-iduronidase enzyme, aiding the breakdown of GAGs.
Despite its benefits, ERT presents several limitations:

It does not penetrate the blood-brain barrier (BBB), limiting its effect on neurological symptoms
Patients require lifelong weekly infusions
The high cost of ERT poses financial challenges for many patients

2. Hematopoietic Stem Cell Transplantation (HSCT)
HSCT is regarded as a potentially curative option, especially for severe cases like Hurler syndrome when performed at an early stage. HSCT can restore enzyme production and prevent further neurological decline.
However, this approach has notable risks:

High mortality rates associated with the procedure
Limited availability of suitable donors
Prolonged immune suppression following transplantation

3. Supportive Care
Since MPS I affects multiple organ systems, supportive care plays a crucial role in enhancing patients' quality of life. Common supportive treatments include:

Physical therapy to maintain mobility
Orthopedic surgeries to manage skeletal complications
Hearing aids and vision correction
Respiratory support to address breathing challenges

Emerging Therapies in the Mucopolysaccharidosis I Drugs Market

The Mucopolysaccharidosis I Drugs Market is witnessing innovation through promising therapies such as gene therapy, intrathecal enzyme therapy, and substrate reduction therapy.

1. Gene Therapy
Gene therapy is emerging as a potentially curative treatment that offers a one-time intervention. Leading candidates in clinical trials include:

RGX-111 (REGENXBIO Inc.) – An adeno-associated virus (AAV)-based gene therapy designed to target neurological symptoms
SB-318 (Sangamo Therapeutics) – A genome-editing therapy using zinc finger nucleases (ZFNs)

These therapies aim to deliver functional copies of the IDUA gene, promoting enzyme production and halting disease progression.

2. Intrathecal Enzyme Therapy
To address ERT's limitation in crossing the blood-brain barrier, researchers are exploring intrathecal enzyme administration, which delivers the enzyme directly into the cerebrospinal fluid. This innovative approach is currently in clinical trials and shows promise for treating neurological complications.

3. Substrate Reduction Therapy (SRT)
SRT aims to limit GAG synthesis, thereby reducing their accumulation. While still in the early stages of development, these therapies may complement existing treatments in the future.

Challenges and Unmet Needs in the Mucopolysaccharidosis I Treatment Market

Despite advancements in therapies, several challenges persist in the Mucopolysaccharidosis I Treatment Market:

Limited availability and high costs of gene therapies
Persistent gaps in treating neurological symptoms
Delayed diagnosis and misclassification in certain regions
Financial burdens linked to orphan drug pricing and reimbursement issues

Addressing these gaps will require continued innovation, improved healthcare policies, and enhanced global access to effective treatments.

Key Players in the Mucopolysaccharidosis I Drugs Market

Several pharmaceutical and biotechnology companies are actively developing therapies in the Mucopolysaccharidosis I Drugs Market. Notable players include:

Sanofi (Aldurazyme – ERT)
BioMarin Pharmaceutical (Gene therapy research for MPS disorders)
REGENXBIO Inc. (RGX-111 – AAV-based gene therapy)
Sangamo Therapeutics (SB-318 – Gene editing therapy)
Ultragenyx Pharmaceutical (Investigating innovative therapies for MPS disorders)

Future Outlook of the Mucopolysaccharidosis I Market

The Mucopolysaccharidosis I Market is expected to expand significantly as gene therapies, improved diagnostic methods, and emerging treatments continue to advance. Increasing efforts to improve affordability and global access will also shape the market's trajectory.

Latest Reports Offered By Delveinsight

About DelveInsight

DelveInsight is a market research and consulting firm specializing in life sciences and healthcare. We deliver valuable insights to help pharmaceutical, biotechnology, and medical device companies succeed in a competitive and rapidly changing industry.

Contact Information
Kanishk
Email: kkumar@delveinsight.com